MA41790B1 - Dérivé de morphinane - Google Patents

Dérivé de morphinane

Info

Publication number
MA41790B1
MA41790B1 MA41790A MA41790A MA41790B1 MA 41790 B1 MA41790 B1 MA 41790B1 MA 41790 A MA41790 A MA 41790A MA 41790 A MA41790 A MA 41790A MA 41790 B1 MA41790 B1 MA 41790B1
Authority
MA
Morocco
Prior art keywords
represent hydrogen
ring
atoms
carbon atoms
carbon atom
Prior art date
Application number
MA41790A
Other languages
English (en)
Other versions
MA41790A (fr
Inventor
Hiroshi Nagase
Hideaki Fujii
Akiyoshi Saitoh
Eriko Nakata
Masaaki Hirose
Isao Ooi
Kohei Hayashida
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41790(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of MA41790A publication Critical patent/MA41790A/fr
Publication of MA41790B1 publication Critical patent/MA41790B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dérivé de morphinane représenté par la formule générale (i) suivante : (où r1 représente l'hydrogène, un alkyle en c1-10, un cycloalkylalkyle où le fragment cycloalkyle a 3 à 6 atomes de carbone, et le fragment alkylène a 1 à 5 atomes de carbone, etc.,r2 représente cycle hétérocyclique contenant 1 à 4 hétéroatomes choisis parmi n, o et s et au moins un atome de carbone en tant qu'atomes constituant le cycle, contenant au moins un ensemble d'atomes constituant le cycle adjacents liés par une double liaison, et en outre substitué par au moins un groupe oxo,y se lie à un atome de carbone en tant qu'atome constituant le cycle de r2, r3, r4 et r5 représentent l'hydrogène ; hydroxy, etc., r6a et r6bre représentent l'hydrogène, etc., r7 et r8 représentent l'hydrogène, etc., r9 et r10, qui sont identiques ou différents, représentent l'hydrogène, etc.,x représente o ou ch2, ety représente c(=o)),un tautomère ou stéréoisomère du composé, ou un sel pharmaceutiquement acceptable de celui-ci, ou un solvate de celui-ci est utilisé comme anxiolytique médicament, antidépresseur, etc
MA41790A 2015-03-17 2016-03-17 Dérivé de morphinane MA41790B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015054079 2015-03-17
PCT/JP2016/058475 WO2016148232A1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Publications (2)

Publication Number Publication Date
MA41790A MA41790A (fr) 2021-06-02
MA41790B1 true MA41790B1 (fr) 2022-02-28

Family

ID=56919074

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41790A MA41790B1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Country Status (24)

Country Link
US (4) US10442802B2 (fr)
EP (2) EP3974430A1 (fr)
JP (4) JP6692345B2 (fr)
KR (2) KR102551969B1 (fr)
CN (3) CN113292559B (fr)
AU (2) AU2016234222C1 (fr)
BR (1) BR112017019805B1 (fr)
CA (1) CA2979023C (fr)
CY (1) CY1124908T1 (fr)
DK (1) DK3272750T3 (fr)
ES (1) ES2904511T3 (fr)
HK (1) HK1249900A1 (fr)
HU (1) HUE057266T2 (fr)
IL (1) IL254473B (fr)
MA (1) MA41790B1 (fr)
MX (2) MX2021008741A (fr)
MY (1) MY197742A (fr)
PH (1) PH12017501655B1 (fr)
PL (1) PL3272750T3 (fr)
RU (1) RU2762567C2 (fr)
SG (2) SG10201907667RA (fr)
TW (2) TWI778933B (fr)
WO (1) WO2016148232A1 (fr)
ZA (1) ZA201706882B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030382A1 (fr) 2016-08-09 2018-02-15 国立大学法人 筑波大学 Dérivé de morphinane
WO2018052114A1 (fr) * 2016-09-16 2018-03-22 国立大学法人 筑波大学 UTILISATION DE DÉRIVÉS DE MORPHINANE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À UN AGONISTE DES RECEPTEURS OPIOÏDES δ
WO2018066532A1 (fr) * 2016-10-03 2018-04-12 学校法人 星薬科大学 Composition pharmaceutique contenant un dérivé de morphinane et son utilisation en tant qu'analgésique
KR20220035378A (ko) 2019-07-19 2022-03-22 닛뽕 케미파 가부시키가이샤 페놀 유도체의 제조 방법
KR20220035383A (ko) 2019-07-19 2022-03-22 닛뽕 케미파 가부시키가이샤 모르피난 유도체의 제조 방법
WO2022045301A1 (fr) 2020-08-28 2022-03-03 日本ケミファ株式会社 Procédé de préparation d'un dérivé de morphinane à chaîne principale formée d'éther diarylique utilisant un nouveau catalyseur au cuivre

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
CL2004000754A1 (es) 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
CN101155812A (zh) 2005-04-04 2008-04-02 阿斯利康(瑞典)有限公司 新二氮杂螺烷和它们治疗ccr8介导的疾病的用途
JPWO2008001859A1 (ja) 2006-06-30 2009-11-26 学校法人北里研究所 オピオイドδ受容体アゴニスト
JP2010538094A (ja) 2007-09-06 2010-12-09 アレイ バイオファーマ、インコーポレイテッド チロシンキナーゼ阻害剤としてのピラゾロピリジン類
BR112012011465A2 (pt) 2009-10-30 2020-08-25 Janssen Pharmaceutica N .V. pirazinas como moduladores do receptor delta opioide.
US9227971B2 (en) 2010-01-19 2016-01-05 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP6091426B2 (ja) 2010-12-23 2017-03-08 フェニックス ファーマラブス インク 鎮痛剤として有用な新規モルフィナン類
JP2014073964A (ja) 2011-01-28 2014-04-24 Kitasato Institute モルヒナン誘導体
JP6061857B2 (ja) * 2011-09-09 2017-01-18 学校法人北里研究所 モルヒナン誘導体
WO2014021273A1 (fr) * 2012-07-30 2014-02-06 学校法人北里研究所 Dérivés morphinane
JP6163210B2 (ja) 2012-12-14 2017-07-12 パーデュー、ファーマ、リミテッド、パートナーシップ 窒素含有モルフィナン誘導体およびその使用
JP6173431B2 (ja) 2013-03-08 2017-08-02 学校法人北里研究所 モルヒナン誘導体
WO2018052114A1 (fr) 2016-09-16 2018-03-22 国立大学法人 筑波大学 UTILISATION DE DÉRIVÉS DE MORPHINANE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À UN AGONISTE DES RECEPTEURS OPIOÏDES δ

Also Published As

Publication number Publication date
TW201638089A (zh) 2016-11-01
AU2016234222A1 (en) 2017-10-26
CY1124908T1 (el) 2023-01-05
MA41790A (fr) 2021-06-02
CA2979023C (fr) 2023-09-26
US10995092B2 (en) 2021-05-04
CN107614500B (zh) 2021-06-15
JPWO2016148232A1 (ja) 2018-03-08
BR112017019805B1 (pt) 2023-01-31
KR20230104767A (ko) 2023-07-10
EP3272750A4 (fr) 2018-08-08
EP3272750A1 (fr) 2018-01-24
WO2016148232A1 (fr) 2016-09-22
DK3272750T3 (en) 2022-01-03
PH12017501655A1 (en) 2018-03-12
CN113292558A (zh) 2021-08-24
SG11201707427TA (en) 2017-10-30
HUE057266T2 (hu) 2022-05-28
BR112017019805A2 (pt) 2018-05-29
MX2021008741A (es) 2022-11-01
MX2017011824A (es) 2018-04-20
EP3974430A1 (fr) 2022-03-30
CA2979023A1 (fr) 2016-09-22
SG10201907667RA (en) 2019-09-27
AU2020270503A1 (en) 2020-12-17
TW202244044A (zh) 2022-11-16
ES2904511T3 (es) 2022-04-05
IL254473A0 (en) 2017-11-30
AU2020270503C1 (en) 2023-08-10
TWI775723B (zh) 2022-09-01
HK1249900A1 (zh) 2018-11-16
AU2016234222B2 (en) 2020-08-27
CN107614500A (zh) 2018-01-19
JP2022081656A (ja) 2022-05-31
EP3272750B1 (fr) 2021-11-03
KR102551969B1 (ko) 2023-07-05
JP7375076B2 (ja) 2023-11-07
PL3272750T3 (pl) 2022-03-07
US10442802B2 (en) 2019-10-15
US11643411B2 (en) 2023-05-09
RU2762567C2 (ru) 2021-12-21
US20180057493A1 (en) 2018-03-01
AU2016234222C1 (en) 2021-02-11
US20210040094A1 (en) 2021-02-11
ZA201706882B (en) 2022-02-23
US20230159530A1 (en) 2023-05-25
JP2020117533A (ja) 2020-08-06
PH12017501655B1 (en) 2018-03-12
AU2020270503B9 (en) 2023-10-12
JP2024010098A (ja) 2024-01-23
CN113292559B (zh) 2024-04-02
AU2020270503C9 (en) 2024-02-29
RU2017134286A (ru) 2019-04-05
KR20180002616A (ko) 2018-01-08
US20200079775A1 (en) 2020-03-12
MY197742A (en) 2023-07-12
TWI778933B (zh) 2022-09-21
CN113292559A (zh) 2021-08-24
RU2017134286A3 (fr) 2019-04-19
JP6692345B2 (ja) 2020-05-13
AU2020270503B2 (en) 2023-02-02
IL254473B (en) 2022-05-01

Similar Documents

Publication Publication Date Title
MA41790B1 (fr) Dérivé de morphinane
MX2020011501A (es) Compuestos novedosos.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
SV2017005384A (es) Compuestos aminopirimidinilo
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
MA32164B1 (fr) Derive heterocyclique fusionne et son utilisation
AR056043A1 (es) Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR094272A1 (es) Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo
PH12019550083A1 (en) Inhibitors of bruton's tyrosine kinase
MA53370B1 (fr) Procédé et intermédiaires pour la préparation de bilastine
MA50093B1 (fr) Composé pentacyclique
AR116713A1 (es) COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
BR112019006675A2 (pt) derivado heterocíclico nitrogenado bicíclico e composição farmacêutica contendo o mesmo
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MA41885B1 (fr) Mélange d'additifs
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR109042A1 (es) COMPUESTOS MODULARES DE RORg
MX2022004178A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.